276 related articles for article (PubMed ID: 19962744)
1. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.
Eckman JA; Sterba PM; Kelly D; Alexander V; Liu MC; Bochner BS; Macglashan DW; Saini SS
J Allergy Clin Immunol; 2010 Apr; 125(4):889-895.e7. PubMed ID: 19962744
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy.
Savage JH; Courneya JP; Sterba PM; Macglashan DW; Saini SS; Wood RA
J Allergy Clin Immunol; 2012 Nov; 130(5):1123-1129.e2. PubMed ID: 22800401
[TBL] [Abstract][Full Text] [Related]
3. Cat allergen-induced blood basophil reactivity in vitro predicts acute human nasal allergen challenge responses in vivo.
Paterniti M; Kelly DC; Eckman JA; Sterba PM; Hamilton RG; Bochner BS; Macglashan DW; Saini SS
Clin Exp Allergy; 2011 Jul; 41(7):963-9. PubMed ID: 21668817
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function.
Beck LA; Marcotte GV; MacGlashan D; Togias A; Saini S
J Allergy Clin Immunol; 2004 Sep; 114(3):527-30. PubMed ID: 15356552
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.
Macglashan DW; Saini SS
J Allergy Clin Immunol; 2013 Oct; 132(4):906-11.e1-4. PubMed ID: 23791510
[TBL] [Abstract][Full Text] [Related]
7. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
8. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors.
MacGlashan DW; Savage JH; Wood RA; Saini SS
J Allergy Clin Immunol; 2012 Nov; 130(5):1130-1135.e5. PubMed ID: 22800400
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic autoimmune urticaria with omalizumab.
Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
[TBL] [Abstract][Full Text] [Related]
10. Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy.
Gernez Y; Tirouvanziam R; Yu G; Ghosn EE; Reshamwala N; Nguyen T; Tsai M; Galli SJ; Herzenberg LA; Herzenberg LA; Nadeau KC
Int Arch Allergy Immunol; 2011; 154(4):318-27. PubMed ID: 20975283
[TBL] [Abstract][Full Text] [Related]
11. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.
Noga O; Hanf G; Kunkel G; Kleine-Tebbe J
Int Arch Allergy Immunol; 2008; 146(1):66-70. PubMed ID: 18087163
[TBL] [Abstract][Full Text] [Related]
12. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
[TBL] [Abstract][Full Text] [Related]
13. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
MacGlashan D; Saini S; Schroeder JT
J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
[TBL] [Abstract][Full Text] [Related]
14. IgE antibody-specific activity in human allergic disease.
Hamilton RG; MacGlashan DW; Saini SS
Immunol Res; 2010 Jul; 47(1-3):273-84. PubMed ID: 20066506
[TBL] [Abstract][Full Text] [Related]
15. Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.
Oliver JM; Tarleton CA; Gilmartin L; Archibeque T; Qualls CR; Diehl L; Wilson BS; Schuyler M
Int Arch Allergy Immunol; 2010; 151(4):275-84. PubMed ID: 19844128
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab.
Zaidi AK; Saini SS; Macglashan DW
J Allergy Clin Immunol; 2010 Apr; 125(4):902-908.e7. PubMed ID: 20236696
[TBL] [Abstract][Full Text] [Related]
17. Differences in effects of omalizumab on late-phase responses to allergen challenge in the skin and nose at the time of basophil hyporesponsiveness.
Paterniti MO; Breslin LM; Courneya JP; Sterba PM; Hamilton RG; MacGlashan DW; Saini SS
J Invest Dermatol; 2014 Jun; 134(6):1743-1744. PubMed ID: 24366613
[No Abstract] [Full Text] [Related]
18. Omalizumab may not inhibit mast cell and basophil activation in vitro.
Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
[TBL] [Abstract][Full Text] [Related]
19. Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation.
Nopp A; Johansson SG; Ankerst J; Bylin G; Cardell LO; Grönneberg R; Irander K; Palmqvist M; Oman H
Allergy; 2006 Mar; 61(3):298-302. PubMed ID: 16436137
[TBL] [Abstract][Full Text] [Related]
20.
Kowal K; Bielecki P; DuBuske IV; DuBuske LM
Allergy Asthma Proc; 2017 May; 38(3):204-215. PubMed ID: 28441991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
